Bristol-Myers Squibb Foundation awards $1.6 million in grants

Bristol-Myers SquibbThe Bristol-Myers Squibb Foundation announced $1.6 million in grants to four health care institutions in India that will help improve diabetes education, prevention and care and increase health care worker capacity in rural and tribal areas and among the urban poor.

The prevalence of diabetes in India has grown roughly four-fold since the early 1970s - from about 2 percent of the population in 1972 to 8.3 percent today - due to factors ranging from genetic predisposition to lifestyle and dietary changes. The International Diabetes Foundation (IDF) reports that 61.26 million people in India are diagnosed with type 2 diabetes, ranking India second only to China in total cases and third behind the United States (10.9 percent) and China (9.3 percent) in terms of prevalence. By 2030, India will have 101.2 million people with type 2 diabetes, IDF projects.

"Stemming the rising tide of type 2 diabetes in India will require a concerted and sustained effort at the community level to ensure adults have access to the education, preventive measures and care they need to effectively self-manage their disease," said John Damonti, president, Bristol-Myers Squibb Foundation. "The grants we are making today through our Together on Diabetes™ initiative will test new ideas about how diabetes control efforts can be best designed and implemented to help adults in a variety of settings."

The Foundation has employed a similar capacity-building approach with its 10-year-old Delivering Hope™ initiative to address hepatitis B and C in Asia, and its ongoing work to address unmet medical needs, reduce health disparities and build community health care capacity was recognized in late July by CMO Asia with an Asia's Best CSR Practices Award in the Concern for Health category.

The following organizations will receive Together on Diabetes™ grants:

  • Mamta Health Institute for Mother and Child, a national organization based in New Delhi and operating in 14 Indian states, will receive US $706,995 over three years to pilot a study to determine the feasibility of involving India’s lay community health workers (Accredited Social Health Activists) and integrating various systems of medicine including modern and AYUSH, to prevent and control non-communicable diseases, especially type 2 diabetes.
  • All India Institute of Diabetes and Research in Naranpura and Swasthya Diabetes Hospital in Ahmedabad will receive US $465,685 over two years to develop and test a three-setting model to improve access to diabetes education, prevention and care for the poor in rural, tribal and urban settings.
  • Sanjivani Health and Relief Committee in Ahmedabad will receive US $426,374 over four years to conduct a household-by-household study in 348 villages to identify type 2 diabetes and ensure early diagnosis of undetected diabetes among those with pre-diabetes or at high risk of developing diabetes. The study also will determine the prevalence of type 2 diabetes and related complications among the rural poor.

About Together on Diabetes™
Together on Diabetes™ brings together some of the world's most respected and influential health care organizations and academic institutions to develop effective, comprehensive solutions that integrate public health, health care services and supportive community supportive services to improve health outcomes and reduce disease burden.

Since its launch in November 2010, Together on Diabetes™ has awarded $32.57 million in grants to 17 organizations working in 23 states and the District of Columbia in the United States, $1.23 million to two organizations in China and $1.6 million to four organizations in India. The total commitment is $115 million through 2014.

About the Bristol-Myers Squibb Foundation
The Bristol-Myers Squibb Foundation is an independent 501(c)(3) charitable organization whose mission is to reduce health disparities and improve health outcomes around the world for patients disproportionately affected by serious diseases.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...